Please login to the form below

Not currently logged in
Email:
Password:

QVA149

This page shows the latest QVA149 news and features for those working in and with pharma, biotech and healthcare.

Boehringer bags FDA approval for Spiriva-based combo

Boehringer bags FDA approval for Spiriva-based combo

Competition is only expected to increase further in COPD. For example, Novartis is due to enter the US LAMA/LABA category shortly with its QVA149 (glycopyrronium bromide/indacaterol) product, which is

Latest news

  • Novartis files COPD combo in US Novartis files COPD combo in US

    Novartis files COPD combo in US. QVA149 combines long-acting beta agonist with long-acting muscarinic antagonist. ... Novartis is hoping new data from its pivotal clinical trial programmes will help position QVA149 in the market.

  • FDA approves Boehringer COPD spray Striverdi Respimat FDA approves Boehringer COPD spray Striverdi Respimat

    But there is a lot of potential competition in COPD at present, including Novartis' QVA149 (glycopyrronium bromide and indacaterol maleate) and GSK and Theravance's Anoro (umeclidinium bromide and vilanterol).

  • Novartis, Boehringer stake claims to combination COPD market Novartis, Boehringer stake claims to combination COPD market

    Ultibro (formerly QVA149) was the first LAMA/LABA to be approved for marketing in the EU, while rival product Anoro (umeclidinium bromide and vilanterol) from GlaxoSmithKline was the first drug in

  • Novartis' combo COPD inhaler cleared in EU Novartis' combo COPD inhaler cleared in EU

    Ultibro (formerly QVA149) combines the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide with the long-acting beta agonist (LABA) indacaterol, which are already approved as monotherapies in the EU as Seebri

  • FDA queries safety of GSK's Anoro for COPD FDA queries safety of GSK's Anoro for COPD

    GSK will find the COPD market increasing competitive, however, with a panoply of other new COPD combinations coming through the pipeline, including Boehringer Ingelheim/Pfizer's olodaterol/tiotropium, Novartis' QVA149 (glycopyrronium

More from news
Approximately 1 fully matching, plus 19 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics